The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat ...

Two state-of-the-art new technologies for transcatheter tricuspid valve replacements is expanding advanced heart care with ...